Table 4. Clinical outcomes according to different time frame of staged PCI during 3.4 years of follow-up.

Variables	Group 1 (n=316)	Group 2 (n=360)	Group 3 (n=77)	p
In-hospital death	4 (1.3)	2 (0.6)	1 (1.3)	0.592
All death	51 (16.1)	57 (15.8)	17 (22.1)	0.393
Cardiac death	22 (7)	26 (7.2)	7 (9.1)	0.810
TVR	13 (4.1)	17 (4.7)	5 (6.5)	0.670
TLR	35 (11.1)	36 (10)	11 (14.3)	0.543
Non TVR	15 (4.7)	18 (5)	8 (10.4)	0.129
Non-fatal myocardial infarction	10 (3.2)	12 (3.3)	2 (2.6)	0.945
Composite MACE	75 (23.7)	81 (22.5)	27 (35.1)	0.063
Stent thrombosis (%)				0.790
Possible	4 (1.3)	2 (0.6)	0
Probable	0	1 (0.3)	0
Definite	6 (1.9)	6 (1.7)	2 (2.6)
Acute	1 (0.3)	0	0	0.534
Subacute	1 (0.3)	3 (0.8)	0
Late	3 (0.9)	3 (0.8)	0
Very late	5 (1.5)	3 (0.8)	2 (2.5)
STEMI recurrent, non-fatal (%)				0.989
Culprit vessel	7 (2.2)	7 (1.9)	1 (1.3)
Non culprit vessel	4 (1.3)	4 (1.1)	1 (1.3)

Values are presented as number (%). Group 1: multivessel PCI of simultaneous culprit and nonculprit vessels during primary PCI, group 2: staged PCI of nonculprit significant vessel within 1 week of primary PCI, group 3: staged PCI performed 1 week after primary PCI. TVR: target vessel revascularization, TLR: target lesion revascularization, MACE: major adverse cardiac events, STEMI: ST-segment elevation myocardial infarction, PCI: percutaneous coronary intervention